Functional outcomes

Textbook of Neuro-Oncology

Volumn , Issue , 2005, Pages 101-104

  Meyers, Christina A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 43249088011     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-8148-1.50018-8     Document Type: Chapter

References (20)

1. Cerami A, Brines ML, Ghezzi P, Cerami CJ Effects of epoetin alfa on the central nervous system. Semin Oncol 2001, 28:66-70.
2. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: the M. D. Anderson symptom inventory. Cancer 2000, 89:1634-1646.
3. Dantzer R, Wollman EE, Yirmiya R Cytokines and depression: an update. Brain Behav Immun 2002, 16:501-502.
4. Dimeo F Radiotherapy-related fatigue and exercise for cancer patients: a review of the literature and suggestions for future research. Front Radiat Ther Oncol 2002, 37:49-56.
5. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001, 19:2875-2882.
6. Larson S, Dunn AJ Behavioral effects of cytokines. Brain Behav Immun 2001, 15:371-387.
7. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22:157-165.
8. Meyers CA, Weitzner MA, Valentine AD, Levin VA Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16:2522-2527.
9. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C Long-term efficacy and safety of modafinil (Provigil®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Medicine 2000, 1:231-243.
10. National Cancer Institute National Institute of Neurological Disorders and Stroke (November, 2000): Report of the Brain Tumor Progress Review Group http://osp.nci.nih.gov/Prg_assess/PRG/BTPRG.
11. Nissenson AR Epoetin and cognitive function. Am J Kidney Dis 1992, 20:21-24.
12. Raz A Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002, 63:343-347.
13. Scheibel RS, Meyers CA, Levin VA Cognitive dysfunction following surgery for intracerebral glioma: influence of histo-pathology, lesion location, and treatment. J Neurooncol 1996, 30:61-69.
14. Scheibel RS, Valentine AD, O'Brien S, Meyers CA Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 2004, 16:1-7.
15. Sherer M, Meyers CA, BergloffP Efficacy of post acute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer 1997, 80:250-257.
16. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 2002, 99:2252-2254.
17. Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001, 19:1802-1808.
18. Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon-alpha therapy. Sem Oncol 1998, 25(suppl 1):39-47.
19. Virta A, Patronas N, Raman R, et al. Spectroscopic imaging of radiation-induced effects in the white matter of glioma patients. Magn Reson Imaging 2000, 18:851-857.
20. Weitzner MA, Meyers CA, Valentine AD Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995, 7:347-350.